Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Gynecologic 1

Conditions

Colorectal Neoplasms 127Carcinoma, Non-Small-Cell Lung 57Squamous Cell Carcinoma of Head and Neck 46Neoplasms 41Head and Neck Neoplasms 38Neoplasm Metastasis 31Pancreatic Neoplasms 15Colonic Neoplasms 14Lung Neoplasms 13Carcinoma, Squamous Cell 13Breast Neoplasms 13Rectal Neoplasms 12Recurrence 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Melanoma 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Carcinoma 6Solid Tumors 5Gastrointestinal Neoplasms 5Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Neoplasms, Squamous Cell 4Laryngeal Diseases 4Advanced Solid Tumor 4Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Pancreatic Ductal 3Uterine Cervical Neoplasms 2

Interventions

pembrolizumab 14Nivolumab 13Sunitinib 12Axitinib 9cabozantinib 8belzutifan 8Ipilimumab 7Everolimus 5atezolizumab 4Sorafenib 4temsirolimus 3perifosine 3motexafin gadolinium 3Drug Therapy 3spartalizumab 2palbociclib 2liposomal doxorubicin 2lenvatinib 2entinostat 2ciforadenant 2belinostat 2avelumab 2Paclitaxel 2Immunotherapy 2G250 monoclonal antibody 2Fluorouracil 2Docetaxel 2Dexamethasone 2Cetuximab 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Neoplasms × Cetuximab × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03319459 2021-11-22

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
44 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡